Compare FRGT & INM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FRGT | INM |
|---|---|---|
| Founded | 2015 | 1981 |
| Country | Mexico | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.3M | 2.7M |
| IPO Year | 2021 | 2020 |
| Metric | FRGT | INM |
|---|---|---|
| Price | $1.04 | $0.70 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 478.4K | 112.1K |
| Earning Date | 04-13-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 96.85 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,728,922.00 | $4,942,633.00 |
| Revenue This Year | $371.03 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 7.50 |
| 52 Week Low | $0.60 | $0.65 |
| 52 Week High | $3.49 | $7.98 |
| Indicator | FRGT | INM |
|---|---|---|
| Relative Strength Index (RSI) | 40.50 | 37.24 |
| Support Level | $0.62 | N/A |
| Resistance Level | $1.23 | $0.94 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 13.64 | 10.50 |
Freight Technologies Inc is a technology company developing solutions to optimize and automate the supply chain process. Along with its subsidiary, Freight App, Inc, the group is focused on making shipping transparent and efficient. Fr8App provides carriers with increased growth opportunities and shippers with flexibility, visibility, and simplicity for the once-complex process of international over-the-road (OTR) shipping. The company uses its proprietary technology platform to connect carriers and shippers and significantly improve matching and operation efficiency via technologies such as live pricing and real-time tracking, digital freight marketplace, broker, transportation management, fleet management, and committed capacity solutions.
InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The Company's operations consist of two operating and reportable segments, the InMed Pharma segment and the BayMedica Commercial segment. The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease.